Molecular Templates, Inc. (Nasdaq: MTEM), a clinical-stage oncology company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced that its management will provide a corporate update at the forthcoming Evercore ISI HealthCONx BioPharma, MedTools, and Devices Conference, and the BMO Capital Markets Prescriptions for Success Healthcare Conference.

Evercore ISI HealthCONx – BioPharma, MedTools, & Devices ConferenceDate:                          Wednesday, November 28Time:                          7:35 am Eastern TimeLocation:                    Boston Harbor Hotel            Webcast:                    http://wsw.com/webcast/evercore2/mtem/

BMO Capital Markets 2018 Prescriptions for Success Healthcare ConferenceDate:                          Wednesday, December 12Time:                          9:00 am Eastern TimeLocation:                    The Mandarin Oriental, New York

About Molecular Templates   Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases.  For additional information, please visit Molecular Templates’ website at www.mtem.com.

Investor Contact: Adam CutlerChief Financial Officer adam.cutler@mtem.com 862-204-4006

Source: Molecular Templates, Inc.

Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Molecular Templates Charts.
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Molecular Templates Charts.